PMC:7274950 / 10090-10261 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7274950","sourcedb":"PMC","sourceid":"7274950","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7274950","text":"ad skeletal manifestations, organomegaly had decreased or disappeared and hematologic features had improved. However, after 15 to 36 months of ERT interruption, splenomega","tracks":[{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T133","span":{"begin":3,"end":11},"obj":"UBERON:0004288"},{"id":"T6169","span":{"begin":3,"end":11},"obj":"UBERON:0004288"}],"attributes":[{"subj":"T133","pred":"source","obj":"LitCovid-PMC-OGER-BB"},{"subj":"T6169","pred":"source","obj":"LitCovid-PMC-OGER-BB"}]},{"project":"LitCovid-PD-CLO","denotations":[{"id":"T117","span":{"begin":130,"end":132},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"}],"attributes":[{"subj":"T117","pred":"source","obj":"LitCovid-PD-CLO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PMC-OGER-BB","color":"#d8ec93","default":true},{"id":"LitCovid-PD-CLO","color":"#e693ec"}]}]}}